Results 41 to 50 of about 3,103 (173)

The Meandrous Route of Rilpivirine in the Search for the Miraculous Drug to Treat HIV Infections

Viruses
Rilpivirine (RPV, R278474) was highlighted in 2005, two years after the death of Dr. Paul Janssen, as the ideal non-nucleoside reverse transcriptase inhibitor (NNRTI) to treat HIV infections.
Erik De Clercq
doaj   +1 more source

Awareness and intention to use event‐driven and long‐acting injectable pre‐exposure prophylaxis among adolescent and young men who have sex with men and transgender women in Brazil: a cross‐sectional study

Journal of the International AIDS Society
Introduction New pre‐exposure prophylaxis (PrEP) options, including event‐driven and long‐acting injectable, may enhance HIV prevention strategies among adolescents and youth.
Laio Magno, Beo Oliveira Leite, Alexandre Grangeiro, Lorenza Dezanet, Fabiane Soares, Inês Dourado   +5 more
doaj   +1 more source

Impact of Tenofovir Alafenamide Sub‐Dermal Implant Insertion Site Scarring on Acceptability and HIV Prevention Preferences: A Prospective Cohort Study in Durban, South Africa

Journal of the International AIDS Society, Volume 29, Issue 4, April 2026.
ABSTRACT Introduction The CAPRISA 018 Phase I trial evaluated the safety, tolerability and pharmacokinetics of a 110 mg tenofovir alafenamide (TAF) implant for HIV prevention in South African women. This follow‐up cohort study, CAPRISA 097, assessed the long‐term resolution of implant site reactions (ISRs) after implant removal and explored user ...
Tanuja N. Gengiah, Lara Lewis, Ishana Harkoo, Nqobile Myeni, Leila E. Mansoor, Salim S. Abdool Karim, Quarraisha Abdool Karim   +6 more
wiley   +1 more source

Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long‐acting cabotegravir/rilpivirine among early adopters in three U.S. clinics

Journal of the International AIDS Society
Introduction Perspectives on long‐acting injectable cabotegravir/rilpivirine (CAB/RPV‐LA) from HIV health disparity populations are under‐represented in current literature yet crucial to optimize delivery.
Katerina A. Christopoulos, Mollie B. Smith, Priyasha Pareek, Alicia Dawdani, Xavier A. Erguera, Kaylin V. Dance, Ryan S. Walker, Janet Grochowski, Francis Mayorga‐Munoz, Matthew D. Hickey, Mallory O. Johnson, John Sauceda, Jose I. Gutierrez Jr., Elizabeth T. Montgomery, Jonathan A. Colasanti, Lauren F. Collins, Moira C. McNulty, Kimberly A. Koester   +17 more
doaj   +1 more source

Intravenous and Subcutaneous Pharmacokinetic Modeling to Support the Development of Long-Acting Multipurpose Prevention Technology for HIV and Pregnancy

Biomedicines
Background/Objectives: Women and girls, particularly in sub-Saharan Africa, face high risks for both HIV and unintended pregnancy. Inconsistent condom use underscores the need for new multipurpose prevention technologies (MPTs) that combine HIV pre ...
Nathan Engel, Daniel Oliveira, Craig Sykes, Amanda P. Schauer, Jasmine L. King, Thy Le, Soumya Rahima Benhabbour, Mackenzie Cottrell   +7 more
doaj   +1 more source

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE‐2 study

HIV Medicine, Volume 27, Issue 4, Page 572-584, April 2026.
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini, Cassidy Henegar, Lambert Assoumou, Stephane de Wit, Margaret Johnson, Eugenia Quiros‐Roldan, Chris Kenyon, Colin Deschanvres, David Zucman, Frank Post, Roya Movahedi, Laura Comi, Julie Fox, Geoffrey Liegeon, Charlotte Martin, Jonathan Edwards, Giorgio Tiecco, Marc Delforge, Leigh Ragone, Bryn Jones, Jean van Wyk, Michael Aboud, Carl Fletcher, Anton Pozniak, Vani Vannappagari   +24 more
wiley   +1 more source

Real-World Experience with Long-Acting Injectable Cabotegravir/Rilpivirine in HIV Patients with Unsuppressed Viral Load

Viruses
Long-acting injectable cabotegravir/rilpivirine (CAB/RPV-LA) is currently approved as a maintenance therapy for people with HIV (PWH) who are virologically suppressed.
Marcello Trizzino, Luca Pipitò, Pierluigi Francesco Salvo, Federica Zimmerhofer, Andrea Cicero, Gianmaria Baldin, Claudia Conti, Claudia Gioè, Simona Di Giambenedetto, Antonio Cascio   +9 more
doaj   +1 more source

Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects [PDF]

Clinical Pharmacology in Drug Development, 2016
AbstractA randomized, partial‐blind, repeat‐dose, 3‐period crossover study (NCT02027454) assessed the effect of cabotegravir on QT interval in healthy subjects. To achieve a supratherapeutic dose, each subject received cabotegravir 150 mg (30 mg × 5 tablets) every 12 hours for a total of 3 doses over 2 days, matching placebo (every 12 hours) over 2 ...
Lou, Yu, Buchanan, Ann M., Chen, Shuguang, Ford, Susan L., Gould, Elizabeth, Margolis, David, Spreen, William R., Patel, Parul   +7 more
openaire   +2 more sources

Overcoming barriers, driving progress: Clinical science at IAS 2025

Journal of the International AIDS Society, Volume 29, Issue 3, March 2026.
Abstract Introduction The 13th IAS Conference on HIV Science, held in Kigali, Rwanda (13–17 July 2025), highlighted key advances in clinical research. Presentations focused on sustaining HIV treatment and prevention amid financial constraints, innovations in long‐acting oral antiretrovirals, and the management of comorbidities and co‐infections ...
Ezequiel Cordova, Simiso Sokhela, Jasmini Alagaratnam, Juan Ambrosioni   +3 more
wiley   +1 more source

Matrix Approach Assessment of Cabotegravir Drug–Drug Interactions with OAT1/OAT3 Substrates and UGT1A1/UGT1A9 Inhibitors Using Physiologically-Based Pharmacokinetic Modeling

Pharmaceutics
Background/Objective: Cabotegravir (CAB), available as an oral tablet and as a long-acting (LA) nanosuspension for intramuscular injection, is approved as a combination therapy for the treatment, and as a monotherapy for the prevention, of HIV-1 ...
Helen Tracey, Simon T. Bate, Susan Ford, Parul Patel, Jackie Bloomer, Aarti Patel, Kunal S. Taskar   +6 more
doaj   +1 more source